Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study

BACKGROUND: Once-daily glecaprevir coformulated with pibrentasvir (glecaprevir/pibrentasvir) demonstrated high rates of sustained virologic response 12 weeks after treatment (SVR12) in patients with hepatitis C virus (HCV) genotype 1–6 infection. This phase 3 study evaluated the efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Rockstroh, Jürgen K, Lacombe, Karine, Viani, Rolando M, Orkin, Chloe, Wyles, David, Luetkemeyer, Anne F, Soto-Malave, Ruth, Flisiak, Robert, Bhagani, Sanjay, Sherman, Kenneth E, Shimonova, Tatiana, Ruane, Peter, Sasadeusz, Joseph, Slim, Jihad, Zhang, Zhenzhen, Samanta, Suvajit, Ng, Teresa I, Gulati, Abhishek, Kosloski, Matthew P, Shulman, Nancy S, Trinh, Roger, Sulkowski, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137115/
https://www.ncbi.nlm.nih.gov/pubmed/29566246
http://dx.doi.org/10.1093/cid/ciy220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137115/
https://www.ncbi.nlm.nih.gov/pubmed/29566246
http://dx.doi.org/10.1093/cid/ciy220

Ejemplares similares